Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

September 2017

Herpes Zoster y Tofacitinib en Pacientes con Artritis Reumatoide

Arthritis Rheumatol 2014;66:2675–84

Chew R,

Patients who were treated with tofacitinib in the RA clinical development programme were more likely to develop herpes zoster than were those who received placebo.Cases of herpes zoster reported by investigators in the Phase 2, Phase 3 and long-term extension studies of tofacitinib were evaluated. Herpes zoster was noted in 5% of tofacitinib-treated patients; only 7% of these cases were serious, no patients with herpes zoster died and only 10% permanently discontinued tofacitinib treatment.The o...

Keywords:

July 2017

Eficacia y seguridad de Tofacitinib en Monoterapia, Tofacitinib con Metotrexato y Adalimumab con Metotrexato en pacientes con Artritis Reumatoide (ORAL Strategy): Un Ensayo Controlado fase 3b/4, aleatorizado, doble ciego, head-to-head.

Lancet. 2017 Jul 29;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5

Fleischmann R,

Mysler E,

Hall S,

Kivitz A,

Moots R,

Luo Z,

DeMasi R,

Soma K,

Zhang R,

Menon S,

on behalf of the ORAL Strategy investigators

In this first head-to-head non-inferiority trial assessing a JAKi ± MTX directly compared with a TNFi + MTX in patients with RA, tofacitinib (TOF) + MTX showed non-inferiority to adalimumab (ADA) + MTX. Non-inferiority was not shown for TOF monotherapy versus TOF + MTX, or versus ADA + MTX.In this 52-week study, MTX-inadequate responder (IR) patients were randomised 1:1:1 to receive TOF 5 mg BID monotherapy, TOF 5 mg BID + MTX or ADA 40 mg every other week + MTX. The primary endpoint, ACR50 resp...